<p>Alpha Tau Medical（纳斯达克代码：DRTS - 获取免费报告）预计将在 2025 年 3 月 11 日星期三市场开盘前发布其 2025 年第四季度的财报。分析师预计该公司将在本季度宣布每股收益为（$0.13）。个人可以在公司即将发布的 2025 年第四季度财报页面上找到会议电话的详细信息，最新的电话安排定于 2026 年 3 月 13 日星期五东部时间下午 5:00。</p>
<p>获取 <strong>Alpha Tau Medical</strong> 的提醒：</p>
<h2>Alpha Tau Medical 股价下跌 7.3%</h2>
<p>纳斯达克 DRTS 周三开盘价为 $7.07。该公司的市值为 $5.9968 亿，市盈率为 -13.60，贝塔值为 1.02。该公司的 50 日简单移动平均为 $6.80，200 日简单移动平均为 $4.97。Alpha Tau Medical 的一年低点为 $2.30，一年高点为 $8.60。</p>
<h2>机构投资者对 Alpha Tau Medical 的看法</h2>
<p>机构投资者最近增加或减少了对该公司的持股。Envestnet Asset Management Inc. 在第三季度购买了 Alpha Tau Medical 的新股份，价值 $62,000。美国银行（Bank of America Corp DE）在第三季度将其在 Alpha Tau Medical 的持股增加了 2,779.1%。美国银行（Bank of America Corp DE）现在拥有该公司 22,457 股股票，价值 $101,000，此前在该期间又购买了 21,677 股。富国银行（Wells Fargo &amp; Company MN）在第四季度将其在 Alpha Tau Medical 的持股增加了 291.7%。富国银行（Wells Fargo &amp; Company MN）现在拥有该公司 23,500 股股票，价值 $116,000，此前在上个季度又购买了 17,500 股。Millennium Management LLC 在第三季度收购了 Alpha Tau Medical 的新股份，价值约 $170,000。最后，Mariner LLC 在第三季度将其在 Alpha Tau Medical 的持股增加了 185.8%。Mariner LLC 现在拥有该公司 123,250 股股票，价值 $556,000，此前在该期间又购买了 80,129 股。2.65% 的股票由机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>DRTS 最近成为几份分析师报告的主题。花旗集团（Citigroup）在 12 月 10 日的研究报告中将 Alpha Tau Medical 的目标价从 $8.00 下调至 $7.00，并对该公司给予了 “买入” 评级。HC Wainwright 在 12 月 10 日的研究报告中重申了对 Alpha Tau Medical 股票的 “买入” 评级。Zacks Research 在 2 月 17 日的研究报告中将 Alpha Tau Medical 的评级从 “强烈卖出” 上调至 “持有”。最后，Weiss Ratings 在 1 月 21 日的研究报告中重新发布了对 Alpha Tau Medical 股票的 “卖出（d-）” 评级。有两位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 $8.00。</p>
<p><strong>获取我们对 Alpha Tau Medical 的最新分析</strong></p>
<h2>Alpha Tau Medical 公司简介</h2>
<p>（获取免费报告）</p>
<p>Alpha Tau Medical Ltd. 是一家总部位于以色列内斯齐奥纳的医疗技术公司，专注于开发针对实体肿瘤的靶向阿尔法辐射疗法。该公司的核心创新被称为扩散阿尔法发射体辐射疗法（DaRT），利用短寿命的放射性同位素直接在肿瘤组织内或附近释放高能阿尔法粒子。通过利用阿尔法辐射的强大细胞毒性效应，Alpha Tau Medical 旨在提供一种新颖的近距离放射治疗方法，可能克服放射抗性并保护周围健康组织。</p>
<p>该公司的主打产品 Alpha DaRT 目前正在临床研究中评估多种适应症，包括复发性或转移性头颈癌、皮肤癌和其他实体肿瘤。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票超过 Alpha Tau Medical</li>
<li>新发现的富铜 “克拉肯” 区</li>
<li>美国的 1776 再次发生</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>在东部时间上午 9:30 到 10:45 之间交易</li>
<li>白银的挤压正在收紧 - 机会正在形成</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJUUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Alpha Tau Medical 吗？</h2>
<p>在你考虑 Alpha Tau Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alpha Tau Medical 并不在名单上。</p>
<p>虽然 Alpha Tau Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

富国银行

美国银行

DRTS

<p>Alpha Tau Medical（纳斯达克代码：DRTS）将于 3 月 11 日公布 2025 年第四季度财报，分析师预测每股亏损 0.13 美元。该公司获得了显著的机构投资，来自美国银行和富国银行的投资尤为显著。目前，股票市值为 5.9968 亿美元，市场共识评级为 “持有”，目标价格为 8.00 美元。Alpha Tau 专注于针对实体肿瘤的靶向α辐射疗法，其主要产品 Alpha DaRT 正在进行临床评估</p>

<p>Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.</p>
<div class="lb-trans"><p>Alpha Tau Medical（纳斯达克代码：DRTS - 获取免费报告）预计将在 2025 年 3 月 11 日星期三市场开盘前发布其 2025 年第四季度的财报。分析师预计该公司将在本季度宣布每股收益为（$0.13）。个人可以在公司即将发布的 2025 年第四季度财报页面上找到会议电话的详细信息，最新的电话安排定于 2026 年 3 月 13 日星期五东部时间下午 5:00。</p>
</div><p>Get <strong>Alpha Tau Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Alpha Tau Medical</strong> 的提醒：</p>
</div><h2>Alpha Tau Medical Trading Down 7.3%</h2>
<div class="lb-trans"><h2>Alpha Tau Medical 股价下跌 7.3%</h2>
</div><p>NASDAQ DRTS opened at $7.07 on Wednesday. The firm has a market capitalization of $599.68 million, a price-to-earnings ratio of -13.60 and a beta of 1.02. The firm's 50 day simple moving average is $6.80 and its 200 day simple moving average is $4.97. Alpha Tau Medical has a 1 year low of $2.30 and a 1 year high of $8.60.</p>
<div class="lb-trans"><p>纳斯达克 DRTS 周三开盘价为 $7.07。该公司的市值为 $5.9968 亿，市盈率为 -13.60，贝塔值为 1.02。该公司的 50 日简单移动平均为 $6.80，200 日简单移动平均为 $4.97。Alpha Tau Medical 的一年低点为 $2.30，一年高点为 $8.60。</p>
</div><h2>Institutional Investors Weigh In On Alpha Tau Medical</h2>
<div class="lb-trans"><h2>机构投资者对 Alpha Tau Medical 的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical during the third quarter valued at $62,000. Bank of America Corp DE increased its holdings in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo &amp; Company MN raised its position in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo &amp; Company MN now owns 23,500 shares of the company's stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter. Millennium Management LLC acquired a new position in Alpha Tau Medical during the 3rd quarter worth about $170,000. Finally, Mariner LLC lifted its holdings in Alpha Tau Medical by 185.8% during the 3rd quarter. Mariner LLC now owns 123,250 shares of the company's stock worth $556,000 after buying an additional 80,129 shares during the period. 2.65% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该公司的持股。Envestnet Asset Management Inc. 在第三季度购买了 Alpha Tau Medical 的新股份，价值 $62,000。美国银行（Bank of America Corp DE）在第三季度将其在 Alpha Tau Medical 的持股增加了 2,779.1%。美国银行（Bank of America Corp DE）现在拥有该公司 22,457 股股票，价值 $101,000，此前在该期间又购买了 21,677 股。富国银行（Wells Fargo &amp; Company MN）在第四季度将其在 Alpha Tau Medical 的持股增加了 291.7%。富国银行（Wells Fargo &amp; Company MN）现在拥有该公司 23,500 股股票，价值 $116,000，此前在上个季度又购买了 17,500 股。Millennium Management LLC 在第三季度收购了 Alpha Tau Medical 的新股份，价值约 $170,000。最后，Mariner LLC 在第三季度将其在 Alpha Tau Medical 的持股增加了 185.8%。Mariner LLC 现在拥有该公司 123,250 股股票，价值 $556,000，此前在该期间又购买了 80,129 股。2.65% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>DRTS has been the subject of several recent analyst reports. Citigroup cut their target price on Alpha Tau Medical from $8.00 to $7.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, December 10th. HC Wainwright restated a &#34;buy&#34; rating on shares of Alpha Tau Medical in a research report on Wednesday, December 10th. Zacks Research upgraded Alpha Tau Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Alpha Tau Medical in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $8.00.</p>
<div class="lb-trans"><p>DRTS 最近成为几份分析师报告的主题。花旗集团（Citigroup）在 12 月 10 日的研究报告中将 Alpha Tau Medical 的目标价从 $8.00 下调至 $7.00，并对该公司给予了 “买入” 评级。HC Wainwright 在 12 月 10 日的研究报告中重申了对 Alpha Tau Medical 股票的 “买入” 评级。Zacks Research 在 2 月 17 日的研究报告中将 Alpha Tau Medical 的评级从 “强烈卖出” 上调至 “持有”。最后，Weiss Ratings 在 1 月 21 日的研究报告中重新发布了对 Alpha Tau Medical 股票的 “卖出（d-）” 评级。有两位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 $8.00。</p>
</div><p><strong>Get Our Latest Analysis on Alpha Tau Medical</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Alpha Tau Medical 的最新分析</strong></p>
</div><h2>Alpha Tau Medical Company Profile</h2>
<div class="lb-trans"><h2>Alpha Tau Medical 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd. 是一家总部位于以色列内斯齐奥纳的医疗技术公司，专注于开发针对实体肿瘤的靶向阿尔法辐射疗法。该公司的核心创新被称为扩散阿尔法发射体辐射疗法（DaRT），利用短寿命的放射性同位素直接在肿瘤组织内或附近释放高能阿尔法粒子。通过利用阿尔法辐射的强大细胞毒性效应，Alpha Tau Medical 旨在提供一种新颖的近距离放射治疗方法，可能克服放射抗性并保护周围健康组织。</p>
</div><p>The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.</p>
<div class="lb-trans"><p>该公司的主打产品 Alpha DaRT 目前正在临床研究中评估多种适应症，包括复发性或转移性头颈癌、皮肤癌和其他实体肿瘤。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Alpha Tau Medical</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>America’s 1776 happening again</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Trade this between 9:30 and 10:45 am EST</li>
<li>Silver's squeeze is tightening - opportunity forming</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Alpha Tau Medical</li>
<li>新发现的富铜 “克拉肯” 区</li>
<li>美国的 1776 再次发生</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>在东部时间上午 9:30 到 10:45 之间交易</li>
<li>白银的挤压正在收紧 - 机会正在形成</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJUUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRTS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alpha Tau Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Alpha Tau Medical 吗？</h2>
</div><p>Before you consider Alpha Tau Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Alpha Tau Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alpha Tau Medical 并不在名单上。</p>
</div><p>While Alpha Tau Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alpha Tau Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Alpha Tau Medical (DRTS) Expected to Announce Quarterly Earnings on Wednesday

- Alpha Tau Medical 将于 3 月 11 日公布 2025 年第四季度业绩，预计每股收益为（$0.13）。  
- 股价现报 $7.07，市值为 $599.68 百万，分析师对该股票的评级以 “持有” 居多。  
- 公司正在开发靶向 α 辐射疗法，以治疗固体肿瘤，目前正进行临床研究。

Alpha Tau Medical (DRTS) 预计将在周三宣布季度财报